Halozyme Therapeutics, Inc. (HALO)
(Delayed Data from NSDQ)
$19.97 USD
-0.16 (-0.79%)
Updated Jan 17, 2020 03:56 PM ET
3-Hold 3
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 2 3 4 5 S&P |
Strong Buy Buy Hold Sell Strong Sell 500 |
24.66% 17.94% 9.57% 5.30% 2.19% 10.75% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
D Value | F Growth | A Momentum | F VGM
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Zacks News
Why Is Halozyme Therapeutics (HALO) Up 6.1% Since Last Earnings Report?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HALO
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Halozyme Therapeutics (HALO) Looks Good: Stock Adds 5.4% in Session
by Zacks Equity Research
Halozyme Therapeutics (HALO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
ANIK HALO
medical
Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3
by Zacks Equity Research
Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.
JNJ RHHBY HALO TAK
biotechs earnings
Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -41.67% and -21.40%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
HALO
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Halozyme Therapeutics (HALO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HALO
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Roche's New Perjeta Combo Meets Goal in Breast Cancer Study
by Zacks Equity Research
Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
MRK RHHBY PBYI HALO
pharmaceuticals
Halozyme Therapeutics (HALO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 41.18% and -0.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
HALO
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Earnings Preview: Halozyme Therapeutics (HALO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HALO
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Soliris' solid performance is likely to reflect in Alexion's (ALXN) second-quarter 2019 results.
REGN ALXN GILD HALO
biotechs
Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay?
by Zacks Equity Research
Alexion (ALXN) gains 30.7% on solid performance of lead drug Soliris and approval of Ultomiris.
GILD CELG HALO ALXN
biotechs
Halozyme Therapeutics (HALO) Matches Q1 Earnings Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 0.00% and -20.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
HALO
earnings earnings-estimates earnings-outlook earnings-surprise energy industry-outlook zacks-consensus-estimate zacks-rank
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HALO
consensus-outlook earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Top Ranked Momentum Stocks to Buy for March 4th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 4th
TARO HALO DLHC CRMT
auto-tires-trucks medical
Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 50.00% and 1.65%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
HALO
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HALO
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
by Zacks Equity Research
Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.
ACHN HALO ALXN AKTX
biotechs
Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion's key drug like Soliris should drive growth in the fourth quarter of 2018.
REGN ALXN HALO BHC
biotechs
Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
by Zacks Equity Research
Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.
ACHN ALXN HALO AKTX
biotechs
Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure
by Zacks Equity Research
Alexion (ALXN) drives growth on consistent demand for lead drug, Soliris. The label expansion of the drug should further propel sales and combat pricing pressure.
BMY ALXN HALO EXEL
biotechs
Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder
by Zacks Equity Research
Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.
GILD ALXN HALO ANIK
biotechs
Halozyme Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Halozyme Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
HALO
medical
Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 17.39% and -17.20%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
HALO
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Earnings Preview: Halozyme Therapeutics (HALO) Q3 Earnings Expected to Decline
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HALO
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Alexion's (ALXN) Earnings Beat Estimates in Q3, Guidance Up
by Zacks Equity Research
Alexion (ALXN) beats earnings estimates and marginally misses sales estimates in the third quarter of 2018. The company also inks a deal to acquire Syntimmune for $1.2 billion.
GILD HALO ALXN CRSP
biofuels
Halozyme Therapeutics (HALO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 27.27% and 11.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
HALO